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ABSTRACT
Introduction: Carbapenem-resistant Enterobacteriaceae (CRE) infections, with limited
treatment options, pose a significant public health challenge. In 2011, the CDC’s phenotypic
CRE case definition was nonsusceptibility to ≥ 1 carbapenem and resistance to 3rd generation
cephalosporins but changed January 2016 to resistance to any carbapenem (including
ertapenem). This study seeks to determine if this change influenced significant differences in
patient characteristics.
Methods: CRE cases in Metro Atlanta, Georgia were collected from 2011-2016. Cumulative
incidence per 100,000, odds ratios, and ꭓ2 estimates were calculated to identify trends. A
univariable analysis was conducted to examine risk factors. Adjusting for covariates, the final
multivariable model included invasive infection as the outcome and the new definition as the
predictor.
Results: A total of 1,144 CRE cases were confirmed from 2011-2016 in Metro Altanta. CRE
incidence rates for all culture sources decreased pre-and post-definition change from 9.4 to 1.6.
Central venous catheters and ICU stay 7 days prior, had the strongest association with invasive
CRE infections; pre-(OR 5.9, 95% CI 1.4-4.3) and post-(OR 11.2, 95% CI 4.9-25.6) definition
change. In the final model, the new definition (OR 0.6, 95% CI 0.4-0.9) predicted invasive
infection.
Discussion: CRE cases, following the new CRE case definition, had a 40% lower odds of
invasive infections than that of the former. The cause of this shift is unclear as more data on
antibiotic resistance profiles is needed to assess the definition’s overall performance. However,
the impact of the new definition on invasive CRE infections is measurable and warrants further
analysis.

KEYWORDS: Carbapenem-resistance Enterobacteriaceae, antibiotic resistance, CRE risk factors, case
definition.
1

Carbapenem-resistant Enterobacteriaceae (CRE) Case Definition Change: A Comparative Study
of the Georgia Emerging Infections Program, 2011-2015 and 2016

by

JEREMIAH WILLIAMS

B.A., EMORY UNIVERSITY

A Thesis Submitted to the Graduate Faculty of Georgia State University in Partial Fulfillment of
Requirements for the Degree MASTER OF PUBLIC HEALTH
ATLANTA, GEORGIA
30303

2

APPROVAL PAGE

CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) CASE DEFINITION
CHANGE: A COMPARATIVE STUDY OF THE GEORGIA EMERGING INFECTIONS
PROGRAM, 2011-2015 AND 2016
By
JEREMIAH WILLIAMS

Approved:

_____________________________
Committee Chair

_____________________________
Committee Member

_____________________________
Date

3

ACKNOWLEDGEMENTS
God- First and foremost, praises and thanks to the God, the Almighty for guidance throughout
my research work and thesis preparation. Through you, all things are possible.
Dr. Betty Lai– Thank you for your encouragement, patience, guidance, and support through this
whole project. Your lab training and lessons in being a skilled researcher, helped make
completing a project of this magnitude possible.
Dr. Ike Okosun-Thank you for being such a supportive committee chair and for the many lessons
you’ve taught me.
Chris Bower MPH, Dr. Jesse Jacob, Suzanne Segler MPH, Dr. Monica Farley and all my
colleagues at the Georgia Emerging Infections Program- I cannot thank you enough for all the
time you spent guiding me, educating me, and answering my millions of questions throughout
the past year. The experience and knowledge I gained from you at GAEIP will forever impact
my career.
My loving mother-June, my sisters-Latasha and April, my brother-Joshua, my girlfriend-Saron,
my friends Carter, Jessie, Omar, Jesse, Brittni, Adil, Dima, and my mentor Pam
- Your belief in me is both inspiring and unwavering. You all kept me going throughout all the
challenges. Put simply, I could not have done this without you.

Disclaimer: The primary dataset used in this project analysis was collected by the Georgia Emerging
Infections Program (GAEIP). The GAEIP was not involved in the analyses presented in this thesis.
4

AUTHOR’S STATEMENT
In presenting this thesis as a partial fulfillment of the requirements for an advanced degree from
Georgia State University, I agree that the Library of the University shall make it available for
inspection and circulation in accordance with its regulations governing materials of this type. I
agree that permission to quote from, to copy from, or to publish this thesis may be granted by the
author, or in his/her absence, the Associate Dean, College of Health and Human Sciences. Such
quoting, copying, or publishing must be solely from or publication of this dissertation which
involves potential financial gain will not be allowed without written permission of the author.

________________________________________

Signature of Author

5

NOTICE TO BORROWERS
All thesis deposited in the Georgia State Library must be used in accordance with the stipulations
prescribed by the author in the preceding statement.
The author of this thesis is: Student’s Name:
Street Address: ____________________________________________________________
City, State and Zip Code: ____________________________________________________
The Chair of the committee for this thesis is:
Professor’s Name: __________________________________________________________
Department: ______________________________________________________________
College: __________________________________________________________________
Georgia State University
P.O Box 3995
Atlanta, Georgia 30302-3995
Users of this thesis who do not regularly enrolled as students at Georgia State University are
required to attest acceptance of the preceding stipulation by signing below. Libraries borrowing
this thesis for the use of their patrons are required to see that each user records here the
information requested.
NAME OF USER

ADDRESS

DATE

6

Type of Use
(EXAMINATION ONLY
OR COPYING)

Jeremiah Williams
2353 Larchwood Rd Atlanta, GA 30310
jwilliamsmph@gmail.com | (727) 495-4075
EDUCATION________________________________________________________________________
MPH, Georgia State University, Atlanta, GA
May 2018
Concentration: Epidemiology, GPA 3.9
Thesis: Carbapenem-resistant Enterobacteriaceae Case Definition Change: A Comparative Study of the
Georgia Emerging Infections Surveillance Periods 2011-2015 and 2016
B.A., Emory University, Atlanta, GA
Major: Political Science | Minor: Anthropology

May 2012

HEALTH FIELD EXPERIENCE_______________________________________________________
Research Interviewer, Surveillance
February 2017-Present
Georgia Emerging Infections Program, Atlanta, GA
Department of Public Health & Centers for Disease Control and Prevention project
Principal Investigator: Monica Farley, MD.
Focus: Active population-based laboratory surveillance for invasive bacterial disease, incidence of
food-borne diseases, and laboratory confirmed influenza-related hospitalizations, and healthcare
associated infections.
• Conduct telephone interviews for case-control and cohort studies and vaccine verification
• Collect patient data from physicians’ offices and medical facilities
• Process isolates in the laboratory; tracking, database entry, packaging and shipping
• Assist with chart reviews for invasive bacterial diseases, foodborne illness, hospital-associated
infections, and laboratory confirmed influenza-related hospitalizations
Graduate Research Assistant, Project Lead
August 2016 - Present
Georgia State University, School of Public Health, Atlanta, GA
Principal Investigator: Betty S. Lai, Ph.D.
Primary Focus: Growth mindset strategies for teaching Biostatistics Introductory course.
• Project lead for study on growth mindset strategies for teaching Masters-level introductory
Biostatistics
• Developing psychoeducation activities and “open” tasks to be integrated in Biostatistics courses and
coordinating workshops
• Researching and co-authoring publications on post-traumatic stress symptoms, assessment concerns,
and academic performance in children following a natural disaster
• Collaborating with researchers from different fields in the development of manuscripts and abstracts
• Assisting with peer reviews, IRB submission, data entry, and study codebook development
Secondary focus: Posttraumatic stress symptoms, assessment concerns, and academic performance in
children following a natural disaster. Duties include:
• Performing preliminary data analyses using SAS and assisting with data entry
• Drafting study codebook, reviewing and proofing manuscripts, proofing and editing grant
Applications
Summer Public Health Research Intern
June-Aug 2016
Department of Community Affairs-Affordable Housing, Atlanta, GA.
• Evaluated and scored Qualified Allocation Plans for private investors applying for tax credits to
create low income housing developments
• Conducted critical policy research on health outcomes associated with low income housing tax
credit properties in GA
7

TEACHING & TRAINING EXPERIENCE_____________________________________________
Early Childhood Trainer/Consultant
May 2015 – Present
Georgia Training Approval, Bright from the Start, Atlanta, GA
• Customized interactive training to meet the needs of session participants and their respective
childcare facilities, awarding training participants Early Childhood Education and Child
Development Associate credentials
• Conducting state approved training for Early Childcare Professionals and Childcare facility
administrators on topics such as ‘Appropriate Health and Safety Practices in Early Childhood
Facilities" and "Special Needs and Inclusion: Fostering Social Skills in the Preschool Classroom"
Learning Coach-Advisor
Sept 2015-Jan 2016
Strengths-based Family Workers Course, Atlanta, GA
• Assisted family workers such as family advocates and caseworkers in gaining and applying family
development knowledge, goal planning skills and other key competencies in their work and
communities to earn course credentials
• Assessed advisees’ progress through a series of written reports
• Guided advisees in developing a portfolio of all coursework for submission upon course completion
Preschool Lead Teacher-Classroom Manager The Clifton School Decatur, GA Oct 2013-Jan 2016
• Observed children closely, document learning, and use these observations as a basis for planning,
facilitated children’s expression of knowledge through representational media
• Managed 4 teachers in implementing a developmentally appropriate curriculum for 25 preschoolers
ages 3-5
• Provided parents with detailed daily reports that outlining their child’s progress, maintaining daily
records of children’s individual activities, behaviors, identifying early warning signs of emotional
and developmental problems in children
• Trained 5 Childhood Development Associate interns in preschool class settings
Special Needs Pre-Kindergarten Lead Teacher
Sept 2011-Oct 2013
The Emory Walden Autism Center, Atlanta, GA
• Conducted 1:1 therapeutic sessions with children with autism to develop social and conversational
skills
• Oversaw a classroom of 4-5 line teachers and 20 children, 6 of which are children with autism
• Created socialization activities and opportunities with typical peers to teach and build social skills
• Supervised and rotated children to various centers and activities every 15 minutes while keeping a
ratio of 1 teacher per 5 children and at least 2 typical children for every child with autism
• Collected data daily to monitor the progress of all skills being taught, implemented
treatment plans that increase daily life, visual performance, tacting, manding, motor imitation, intraverbal, and other verbal skills

8

LEADERSHIP AND CERTIFICATION_________________________________________________
Teacher Council- Appointed member The Clifton School, Atlanta, GA
Dec 2013-Jan 2016
Drafted proposals to boost school morale and to effectively address teacher and administrative concerns.
Strengths-Based Family Workers Credential (Seven-month professional training)
Dec 2014
Strengths-Based Family Workers Course (SFW), Atlanta, GA.
The SFW course is an enhanced training and credentialing program that ensures family development
workers have the basic knowledge, skills and values for working with families and are equipped to
facilitate a family's ability to obtain and maintain family economic success. Aside from completing a
professional portfolio and a final exam, candidates must master the following core competencies to
receive course credentials:
• Demonstrate professionalism and commitment to ethical practice
• Recognize strength in diversity and difference; demonstrate sensitivity in practice
• Understand and utilize the power of clear, non-judgmental communication
• Demonstrate self-care and lifelong learning
• Apply strengths-based principles to practice with families
• Apply strengths-based principles to agency and community systems
PEER REVIEWED PUBLICATIONS ___________________________________________________
Williams, J.D., Shah, H.J., & Lai, B.S. (2017). Traumatic experiences related to 9/11: Homogeneity of severe
posttraumatic stress disorder symptom profiles in children and adolescents. Academy on Violence and Abuse
Research Review, 12, 1-3.
Williams, J.D., Livings, M., Cathey, R. & Lai, B, (2018). Employing a growth mind-set intervention in a graduatelevel statistics course: Merging research with teaching. SAGE Research Methods Cases.10.4135/9781526449122
Livings, M.S., Williams, J.D, & Lai, B.S. (2017). Wenchuan Earthquake aftermath: Trajectories of posttraumatic
stress symptoms among adolescent survivors. Academy on Violence and Abuse Research Review, 11, 1 – 3.
Lai, B.S., M.J., D’Amico, Livings, M.S., Hayat, Williams, J.D., (2017). (Pending Submission) “A Growth
Mindset Pilot Intervention for a Graduate-Level Statistics Course.” Journal of Statistics Education.

ABSTRACTS AND POSTER PRESENTATIONS _________________________________________
Williams, J.D., 2016 (Summer) “Health and Housing: The Effectiveness of DCA Affordable Housing Policies on
Mitigating Key Social Determinants of Health.” Presented at Georgia Department of Community Affairs.
Williams, J.D., Lee, M.P., Livings, M.S., Lewis, R.M., Shah, H., & Lai, B.S. 2017 “A Growth Mindset
Intervention to Increase Motivation, Self-Efficacy, and Achievement in a Graduate Level Statistics Course.” Poster
accepted for Annual Georgia Public Health Association Conference.
Williams, J.D, Livings, M.S., Shah, H.J., Lewis, R.M & Lai, B.S., 2017 “Enhancing Graduate Student Motivation
and Persistence through a Growth Mindset Intervention.” Center for Excellence in Teaching and Learning
Conference.
Livings, M.S., Greenbaum, J., Lewis, R.M., Williams, J.D., Self-Brown, S., & Lai, B.S. 2017. “A Screening Tool
for Identification of Victims of Commercial Sexual Exploitation of Children.” Annual Georgia Public Health
Association Conference.
Shah, H.J., Lewis, R., Osborne, M., Malmin, N., Wyczalkowski, C., Williams, J.D., Lee, M., Esnard, A.-M., & Lai,
B.S. (2017). “Characterizing discrepancies in school recovery after disasters.” Georgia Public Health Association
Annual Meeting and Conference.

9

Table of Contents
ACKNOWLEDGEMENTS…………………………………………………………………..5
TABLES………………………………………………………………………………………13
FIGURES…………………………………………………………………………………… 13
1. INTRODUCTION……………………………………………………………………14
2. LITERATURE REVIEW……………………………………………………………16
2.1 Carbapenem Use and Increasing Resistance…………………………………..16
2.2 Emergence of CRE and Mechanism for Resistance………………………….. 17
2.3 CRE in the Healthcare Setting…………………………………………………19
2.4 Risk Factors for CRE…………………………………………………………..20
2.5 The Role of Long-Term Care Facilities in the Spread of CRE…………...……22
2.6 Rationale for Case Definition Change…………………………………………22
3. METHODS AND PROCEDURES..…………………………………………………25
3.1 Surveillance Population……..…………………………………………………25
3.2 Case Definition…………………………………………………………………26
3.3 Data Collection………………………………………………………………....26
3.4 Data Analysis……………………………………………………………………27
4. RESULTS…..…………………………………………………………………………..28
4.1 Descriptive Analysis………………………………………………………….... 28
4.2 CRE Organism Distribution….…………………………………………………33
4.3 Risk Factors………………..…………………………………………………….34
4.4 Univariable Analysis……..……………………………………………………..36
4.5 Multivariable Analysis..…………………………………………………………37
5. DISCUSSION AND CONCLUSION.…...……………………………………………39
5.1 Limitations..……………………………………………………………………...40
5.2 Recommendations and Future Studies…………………………..………………41
REFERENCES….….………………………………………………………………………42

12

LIST OF TABLES
Table 1: Carbapenemases
Table 2. CRE Case Definitions
Table 3: Study Period 1 Patient Characteristics by Culture Source
Table 4: Study Period 2 Patient Characteristics by Culture Source
Table 5: Study Period 1 - Risk Factors: Univariable Comparisons
Table 6: Study Period 2- Risk Factors: Univariable Comparisons
Table 7: Study Period 1 - Risk Factors: Univariable Logistic Regression Comparisons
Table 8: Study Period 2 - Risk Factors: Univariable Logistic Regression Comparisons
Table 9: Final Multivariable Model for the association between New Case Definition and
Invasive CRE infections

LIST OF FIGURES
Figure 1: Georgia Emerging Infections Program Surveillance Area
Figure 2: Crude Annual Cumulative Incidence of CRE Cases in HD3
Figure 3: Crude Annual Mortality Rate for CRE Deaths in HD3
Figure 4: CRE Cases by Culture Source Per Study Period
Figure 5: Organism Breakdown
Figure 6: Equation: Final Multivariate Logistic Regression Model of the Association between
New Case Definition and Invasive CRE Infections

13

1. INTRODUCTION

Carbapenem-resistant Enterobacteriaceae, (CRE) have become a major public health
issue across the globe (Tamma, Huang, Opene, & Simner, 2016). These gram-negative
organisms are multidrug-resistant pathogens that cause severe infections and have been
associated with high mortality rates (Guh et al., 2015). According to a 2013 Morbidity and
Mortality Weekly Report (MMWR), CRE-related infections mortality rates can be as high as
40% to 50% (Patel et al. 2008; Schwaber et al., 2011; Chitnis et al., 2012; Vital Signs:
Carbapenem-resistant Enterobacteriaceae, 2013). CREs commonly occur in healthcare settings,
such as hospitals and long-term care facilities (LTCFs)(Guh et al., 2015). A cause of challenging
healthcare-associated infections such as bacteremia, and often hidden throughout the hospital
environment, clinicians have fewer treatment options since the emergence of CREs (Guh et al.,
2015). In the United States, the percentage of healthcare-associated infections caused by
carbapenemase-resistant Enterobacteriaceae rose from 1.2% to 4.2%, 2001-2011 (Jacob et al.,
2013; Chea et al., 2015). During which, the Klebsiella species accounted for the greatest
increase, approximately 10% (Jacob et al., 2013; Chea et al., 2015).
Enterobactericeae are a large diverse family of gram-negative bacteria. Many of which
are not pathogenic, however the Georgia Emerging Infections Program (Georgia EIP) tracks
carbapenem resistance to Escherichia coli, Klebsiella spp., and Enterobacter spp through it’s
Multi-site Gram-negative Surveillance Initiative (MuGSI) (CDC, 2015). MuGSI operates under
the direction of the Centers for Disease Control and Prevention’s (CDC) Healthcare-Associated
Infections Community Interface (HAIC) (CDC, 2015).
Clinical cultures for patients suspected of CRE may present colonization (i.e. presence of
CRE bacteria on a body surface but no clinical evidence of an infection) as Georgia EIP’s
surveillance is limited to urine and sterile sites (i.e. blood, bone, internal body sites, etc.) (CDC,
14

2015). Likewise, there is constant pressure to refine the case definition used to identify CRE and
carbapenemase-producers among CREs, as the carbapenemase enzyme has been recognized as a
driving factor in the spread of CRE (Chea et al., 2015).
In November 2011, the CDC developed it’s first surveillance definition for CRE:
Enterobacteriaceae that are non-susceptible to one of the following carbapenems: doripenem,
meropenem, or imipenem AND resistant to all of the following third- generation cephalosporin;
ceftriaxone, cefotaxime, and ceftazidime (Chea et al., 2015). January 2016, the CDC modified its
surveillance definition for CRE to align with other state reportable definitions and a recently
released Council for State and Territorial Epidemiologist (CSTE) position statement (Chea et al.,
2015). The new phenotypic case definition added ertapenem, changed the breakpoint for
carbapenems to resistant, and dropped the cephalosporin requirement. Resistance to ertapenem
was not required in the previous case definition as it was considered too sensitive and had a
different breakpoint from the other carbapenems (Chea et al., 2015). However, growing
ertapenem resistance among CREs made its inclusion in the new definition necessary (Chea et
al., 2015). This new definition was projected to be more sensitive for detecting carbapenemase
producers than the previous definition but also had lower specificity (Chea et al., 2015)
Though the case definition change was intended to more accurately identify more
positive CRE cases, the effects of the case definition change on the CRE patient population are
not well described. As such, a thorough evaluation of how this recent case definition change
could provide guidance on how to continue improving CRE surveillance as well as provide
valuable epidemiological data specific to the metropolitan Atlanta area.
The aim of this analysis is to compare and describe the differences in CRE cases from
2011-2015 study period (study period 1) and 2016 CRE study period (study period 2) in the
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metropolitan Atlanta area. Specifically, the following hypothesis will be tested: If the current
CDC CRE surveillance definition was designed to be more simple and sensitive, surveillance
efforts in Atlanta should have an impact on patient profiles.
This study will contribute to the Georgia EIP’s effort to conduct accurate CRE
surveillance and will help provide a better understanding of the CRE patient population. Thus,
study findings will also serve as a guide in designing prevention and control measures to combat
the spread of CREs. Several questions will direct this study: 1) Was there a significant difference
in CRE incidence rates between the two study periods? 2) Did the incidence rates differ between
hospitals and long-term care facilities? 3) Were there differences between cases with positive
urinary cultures and invasive infections regarding demographics, healthcare exposures, and
device-associated infections
2. LITERATURE REVIEW
2.1 Carbapenem Use and Increasing Resistance
Carbapenems were first developed in the 1980s and derived from thyanamycin (Perez,
Rodrigues, & Dias, 2015). Imipenem and meropenem were the first of this drug class and are
considered broad-spectrum antibiotics, placing them at the forefront in the fight against hard-totreat nosocomial infections. During this period, carbapenems were effective against the vast
majority of Enterobacteriaceae (Papp-Wallace, Endimiani, Taracila, & Bonomo, 2011).
By the 1990s, Enterobacteriaceae began showing resistance to cephalosporins, through
developing an enzyme that disables these agents called extended-spectrum β-lactamase (Perez,
Rodrigues, & Dias, 2015). Therefore, clinicians were forced to use carbapenems, which
remained susceptible (Rahal, 1998). Both are β-lactam antibiotics (beta-lactam antibiotics) which
is a class of broad-spectrum antibiotics, comprised of anti-microbial agents that have a β-lactam
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ring in their molecular framework (Holten & Onusko, 2000). This class of antibiotics is further
divided into several subgroups; cephalosporins (cephems), penicillin offshoots (penams),
carbapenems, and monobactams (Holten & Onusko, 2000). Ertapenem, another carbapenem with
an extended half-life and once-daily dosing, was introduced in 2001 (Perez, Rodrigues, & Dias,
2015). Consequently, this carbapenem was a favorable option for treating community cases
(Livermore, Sefton, & Scott, 2003). Launched in 2005, doripenem is the latest addition to the
carbapenem class of antibiotics (Bazan, Martin, & Kaye, 2009).
Similar to imipenem and meropenem, doripenem has broad-spectrum activity and is
effective against Pseudomonas aeruginosa, prompting more use of carbapenems (Bazan, Martin,
& Kaye, 2009). A study, involving 35 university hospitals in the United States, found that
carbapenem use rose by 59% from 2002 to 2006 (Pakyz, MacDougall, Oinonen, & Polk, 2008).
By the early 2000’s, carbapenem resistance in Enterobactiericeae was documented in
North America and began spreading in the United States after a series of hospital-related
outbreaks in the Northeast (Perez, Rodrigues, & Dias, 2015). This resistance was due, in part, to
the development of another enzyme called carbapenemases. Carbapenemases are β-lactamases
with the ability to hydrolyze cephalosporins, monobactams, penicillins, and carbapenems
(Queenan & Bush, 2007).
2.2 Emergence of CRE and Mechanisms for Resistance
Like other pathogens, CRE can be transmitted person-to-person. Yet, there are many
multiple mechanisms that contribute to carbapenem resistance (Capone et al., 2013). One of
which is via plasmids (Capone et al., 2013). Plasmids are particularly predominant among
Enterobacteriaceae and can reproduce irrespectively of chromosomal DNA (Carattoli, 2011;
Schwaber, Carmeli, & Harbarth, 2011; Plasmid | microbiology, 2018). The resistance gene can
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be implanted into plasmids of gram-negative bacteria and can transfer resistance not only from
patient to patient but also from ne species of bacteria to another species, resulting in more
species becoming drug resistant (Capone et al., 2013).
Carbapenemases are part of several molecular classes; A, B, and D β-lactamases (see
Table 1) (Queenan & Bush, 2007 ).
Table 1: Carbapenemases
Classes
Enzymes
Class A
*KPC(1-10), SME, IMI,
NMC, GES
Class B
IMP, VIM, GIM, SPM,
(metallo-βNDM-1
lactamases)
Class D
OXA

Most Common Bacteria
Enterobacteriaceae (seen rarely in P.
aeruginosa)
P. aeruginosa, Enterobacteriaceae,
Acinetobacter spp.
Acinetobacter spp., P. aeruginosa and
rare Enterobacteriaceae

*Plasmid, [A] KPC-K. pneumoniae carbapenemase, SME- S. Marcesens enzyme, NMC-Not Metallo Carbapenemase, IMI-IM hydrolyzing β-lactamase, GES-Guiana extended
spectrum; [B] VIM-Verona Integron Encoded MBL; NDM-1-New Delhi β-lactamase; [D] Oxacilin hydrolyzing. Enzyme Specific Activity Spectrum: KPC(1-10)- All β-lactams;
SME, IMI, NMC -Carbapenem, Aztreonam but not 3rd & 4th generation Cephalosporins; GES-Imipenem and 3rd / 4th generation; IMP, VIM, GIM,SPM- All β-lactams,
susceptible to aztreonam and NDM-1 variable AZT resistance; IMI, NMC, GES- Weak activity against carbapenems.
(The Pediatric Infectious Disease Journal, 2010).

Enzymes in the A and D classes break down carbapenems through a serine-based
process, while those in the B class are metallo-β-lactamases and involve zinc in the process
(Queenan & Bush, 2007 ). The A class carbapenemases consist of the blaKPC (KPC1-10) blaSME,
blaGES, blaIMI, and blaNMC enzyme groups (Queenan & Bush, 2007 ). KPC carbapenemases are
widely distributed and originate from plasmids in Klebsiella pneumoniae (Queenan & Bush,
2007 ). Carbapenem resistance due to the presence of a class A carbapenemase was initially
observed in 1996 from an isolate of Klebsiella pneumoniae in North Carolina (Yigit et al.,
2001).
In 2006, KPC-producing strains of Klebsiella pneumoniae (KPC-Kp) were connected
with outbreaks in the United States; mostly in the Northeast and Arizona (Temkin et al., 2014).
In one of these KPC-Kp-associated outbreaks, 24 patients in a New York City Hospital were
affected resulting in a 33% fatality rate (Woodford et al., 2004). In 2008, KPC-Kp strains were
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also identified in Greece, Israel, and Italy (Leavitt et al., 2007; Maltezou et al., 2009; Mezzatesta
et al., 2011; Pournaras et al., 2009; Schwaber et al., 2011).
Due to horizontal transfer, KPC was soon found in other types of the Enterobacteriaceae
(Martirosov & Lodise, 2016). Though differences exist between regions, one study found that
KPCs exist in 4% of Escherichia coli and 10% of Klebsiella pneumoniae (Marsik and Nambiar,
2011). KPCs are now the most widespread carbapenemase (Munoz-Price et al., 2013).
The emergence of other carbapenemases is also well documented. The B class
carbapenemases consist of the, blaIMP, blaVIM, blaGIM, blaSPM, and blaNDM-1. Initially discovered in
1997 in Pseudomonas aeruginosa isolates, blaVIM was detected in Enterobacteriaceae from
Greece in 2001 (Lauretti et al., 1999; Miriagou et al., 2003). In 2009, blaNDM-1 was reported in
isolates from Swedish patient with a urinary tract infection (UTI) in an Indian medical center
(Yong et al., 2009).
The D class includes the blaOXA enzymes and are typically found in Acinetobacter
baumannii (Bush et al., 1995; Queenan and Bush, 2007; Walther-Rasmussen and Hoiby, 2006).
There are 120 blaOXA variants, of which over one-third hydrolyze carbapenems (Bush et al.,
1995; Queenan and Bush, 2007; Walther-Rasmussen and Hoiby, 2006).
2.3 CRE in the Healthcare Setting
According to the CDC’s 2013 Antibiotic Resistance threat report, CRE-related infections
in the healthcare environments are increasing and considered an urgent threat (2013). The
National Healthcare Safety Network (NHSN) collects antimicrobial susceptibility data on
patients with catheter-associated urinary tract and blood stream infections. Data collected in
2006-2007 showed that carbapenem resistance was observed in 0.9% of Escherichia coli
infections and in 10.8% of Klebsiella pneumoniae infections in hospital patients with central
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line–associated bloodstream infections (CLABSIs) (Hidron et al., 2008). NHSN reported a rise
in carbapenem resistance, in 2009-2010, from 10.8% to 12.8% of Klebsiella pneumoniae cultures
associated with CLABSIs (Sievert et al., 2013).
At least one healthcare associated CRE infection occurred in 3.9% of short-stay acutecare hospitals (ACH) and 17.8% of LTACHs in 2012 (Martirosov & Lodise, 2016; Vital Signs:
Carbapenem-Resistant Enterobacteriaceae, 2013). By 2012, CRE had spread to 42 states, and the
number of Enterobacteriaceae that were CREs had risen fourfold over a 10-year span (Vital
Signs: Carbapenem-resistant Enterobacteriaceae, 2013). During this time frame, carbapenem
resistance in Klebsiella pneumoniae catheter-associated UTIs (CAUTIs) rose from 10.1% to
12.5% as well (Hidron et al., 2008; Sievert et al., 2013; Martirosov & Lodise, 2016). Similarly,
increasing rates of carbapenem resistance can be seen in patients with ventilator-associated
pneumonia (VAP) ( Hidron et al., 2008; Sievert et al., 2013; Martirosov & Lodise, 2016).
Carbapenem resistance among Klebsiella pneumoniae and Escherichia coli cases with VAP
increased from 3.6% and 1.8% to 11.2% and 3.5%, respectively ( Hidron et al., 2008; Sievert et
al., 2013; Martirosov & Lodise, 2016). CRE infections occur at varying rates and are not limited
to the hospital environment as they are found in all types of healthcare facilities; such as
convalescent facilities and long-term acute care hospitals (LTACHs) (Martirosov & Lodise,
2016; Hayden et al., 2014; Marquez et al., 2013).
2.4 Risk Factors for CRE
Understanding the epidemiology of the risk factors associated with CRE infections
essential in developing effective control strategies such as early intervention in terms of
treatment and appropriate antibiotic therapy. According to a landmark comprehensive study that
examine the emergence of CRE across the globe, “Carbapenem-resistant Enterobacteriaceae:
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Epidemiology and Prevention,” by Gupta et al., the most prominent risk factors for CRE
infections are extensive time in medical facilities, exposure to medical instruments, such as
indwelling devices, and previous exposure to antibiotics (2011). All of which were demonstrated
in a matched-case control study conducted by Patel et al. (2008). The researchers uncovered a
strong association between carbapenem-resistant Klebsiella pneumoniae infections and organ or
stemcell transplants, artificial ventilation to support breathing, number of hospitalizations,
prolonged length of stay, and previous use of carbapenems or cephalosporins (Patel et al., 2008).
Studies that have examined the clinical characteristics of CRE cases have found that the
severely-ill, debilitated, elderly, immunosuppressed, and those with extensive comorbidities are
at risk for CRE infections (Gupta et al., 2011; Kim et al., 2014; Martirosov & Lodise, 2016; Patel
et al., 2008; Perez & Van Duin, 2013; Zurawski, 2014). Specifically, the elderly, burn victims,
and severely-ill patients with bacteremia commonly experience the most challenging outcomes
(Perez & Van Duin, 2013; Tumbarello et al., 2012; Zarkotou et al., 2011). Furthermore, patients
in intensive-care units (ICU) had an increased risk of CRE-related infections compared those in
non-critical care wards (Gupta et al., 2011; Kim et al., 2014; Martirosov & Lodise, 2016; Patel et
al., 2008; Zurawski, 2014).
Considering the frequency in which microbes change and adapt, many find the
association between previous antibiotic therapy with carbapenems a primary cause of rising CRE
rates. However, results from several studies show that it is, actually, the cumulative treatment of
antibiotics rather than treatment of a single antibiotic class, that fuels CRE rates (Gallagher et al.,
2014; Marchaim et al., 2012; Patel et al., 2011). This response to a consistent influx of and
collective exposure to antimicrobials occurs by disturbing the colonization of the “good
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bacteria,” rendering patients more susceptible to resistant pathogens like CRE (Patel et al.,
2011).
2.5 The Role of Long-Term Care Facilities in the Spread of CRE

The association between LTCFs and the spread of CREs has been highlighted in a
number of studies and evidence suggests LTCFs may play a central role among the list of risk
factors responsible for the proliferation of CREs (Perez et al., 2010; Perez & Van Duin, 2013).
Additionally, researchers determined from a retrospective observational study, that over 50% of
CRE-linked infections were transferred from an LTCF (Perez et al., 2010). Data collected from
an investigation on carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae
in a group of medical facilities showed 75% of carbapenem-resistant Klebsiella pneumoniae
came from LTCFs (Perez & Van Duin, 2013). One study that focused on movement of patients
with carbapenem-resistant associated bloodstream infections between hospitals and LTCFs
determined that of the 42% that survived their index admission, just 32% were discharged, and
overall, readmissions occurred frequently (Perez & Van Duin, 2013; Neuner et al., 2011).
Transfers from LTCFs or another medical facility is linked to carbapenem-resistance in patients
colonized or infected with Enterbacteriaceae. Though researchers recognize LTCFs to be at the
forefront of the emergence and transmission of CREs, it is important to note that location of care
can and often overlaps with other risk factors.
2.6 Rationale for Case Definition Change
Carbapenem resistance within the Enterobacteriaceae family is uniquely challenging.
There are over 70 Enterobacteriaceae classes with a variety of mechanisms that can create
carbapenem resistance (CDC, 2015). Irrespective of the mechanism behind the carbapenem
resistance, all CRE are typically multidrug-resistant pathogens that warrant immediate attention
in healthcare settings to prevent and control transmission. However, carbapenemase-producing
22

CREs (CP-CRE) are considered to be the prime cause for the proliferation of CRE in the United
States and thus have been the focus for aggressive prevention strategies (CDC, 2015; Chea et al.,
2015). Distinguishing CP-CRE from non-CP-CRE is the most reliable approach to thwarting the
spread of CRE (CDC, 2015; Chea et al., 2015). Mechanism testing, however does not serve as a
guide in making therapeutic decisions and it is not commonly performed in clinical laboratories
across the US (CDC, 2015; Chea et al., 2015). In the absence of mechanism testing, phenotypic
definitions, regarding a pathogens antibiotic susceptibility pattern, are the principal method for
identifying CP-CRE (CDC, 2015). It is important to note that no phenotypic definition is 100%
accurate in differentiating CP-CRE from non-CP-CRE (CDC, 2015; Chea et al., 2015).
The previous phenotypic CRE surveillance definition (nonsusceptibility to doripenem,
meropenem, or imipenem AND resistant to all third-generation cephalosporins; ceftriaxone,
cefotaxime, and ceftazidime) was intended to capture more CP-CRE (Chea et al., 2015).
However, there were several issues; automated testing instruments were not testing low enough,
the CDC CRE case definition did not align with state-reportable definitions, and low sensitivity
for capturing CP-CRE (CDC, 2015; Chea et al., 2015). The challenge was due to the sheer
number of antibiotics involved and the different standards for specific antibiotics (i.e.
nonsusceptibility for carbapenems and resistance for cephalosporins). Moreover, ertapenem,
another carbapenem, was initially excluded in the definition because of apprehension regarding
its low cutoff for nonsusceptibility ( ≥1 mcg/ml) (CDC, 2015; Chea et al., 2015).
In time, concerns over whether the original definition missed CP-CRE prompted more
investigation on its performance. Eventually, the CDC began identifying CRE that contained the
KPC gene (blaKPC) and showed resistance to ertapenem but were susceptible other carbapenems
(Humphries & McKinnell, 2016). The results from a validation study conducted by the CDC
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indicated that some of KPC-producing Klebsiella species might be overlooked by not including
ertapenem in the definition (Arnold et al., 2011). Also, some clinical laboratories only tested
ertapenem, meaning CRE would not be identified with the previous definition (CDC, 2015).
Lastly, CRE producing OXA-48 carbapenemases may not be resistant to third-generation
cephalosporins and thus would not be identified using the former definition (CDC, 2015).
Therefore, to make testing more simple and reliable, considerable effort was put into creating a
more suitable set of criteria for identifying CREs (CDC, 2015; Chea et al., 2015). By January
2016, the CDC changed its CRE definition to resistance to imipenem, meropenem, doripenem, or
ertapenem (see Table 2) (CDC, 2015; Chea et al., 2015).
Table 2: CRE Case Definitions
Category
Carbapenemnonsusceptible
Enterobacteriaceae

Carbapenemnonsusceptible
Enterobacteriaceae

2011-2015
Species
Carbapenem susceptibility phenotype
Escherichia coli
Intermediate or resistant to:
Klebsiella pneumoniae
Imipenem (MIC ≥2),
Klebsiella oxytoca
Meropenem (MIC ≥2),
Enterobacter cloacae
or Doripenem (MIC ≥2)
Enterobacter
AND resistant to:
aerogenes
Ceftazidime (MIC ≥16),
Ceftriaxone (MIC ≥4),
and Cefotaxime (MIC ≥4
2016
Escherichia coli
Resistant to:
Klebsiella pneumoniae
Imipenem (MIC ≥4),
Klebsiella oxytoca
Meropenem (MIC ≥4),
Enterobacter cloacae
Doripenem (MIC ≥4),
Enterobacter
or Ertapenem (MIC ≥2)
aerogenes

Including ertapenem in the new definition increased the likelihood of capturing more
non-CP-CRE than that of the former definition (CDC, 2015). Resistance to all third-generation
cephalosporins was omitted from the new CDC CRE definition for several reasons: to make the
definition easier to implement; to adequately address the rise in OXA-48 producing CRE, as they
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may not show resistance to this group of antibiotics and; there was a sufficient amount of
evidence that the inclusion of cephalosporins requirement did not significantly increase
sensitivity and specificity for CP-CRE (CDC, 2015).
A standardized, reliable phenotypic surveillance definition for CRE is vital for prevention.
Accurate diagnoses of CREs, especially those of greatest epidemiological interest such as CPCRE, aids in prevention efforts. A standardized surveillance definition is also essential for
obtaining national burden estimates as it ensures consistent reporting from laboratories across the
country (CDC, 2015; Chea et al., 2015).

3. METHODS AND PROCEDURES
3.1 Surveillance Population
The Multi-site Gram Negative Surveillance Initiative (MuGSI), as part of the Center for
Disease Control (CDC)’s Emerging Infections Program (EIP), conducts active, population-based
laboratory surveillance for carbapenem-resistant gram-negative bacteria.
Figure 1: Georgia Emerging Infections Program Surveillance Area

https://dph.georgia.gov/sites/dph.georgia.gov/files/site_page/Monica%20Farley.pdf
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Georgia is one of eight EIP sites nationwide that conducts surveillance for carbapenemresistant Enterobacteriaceae (CRE). The surveillance catchment area for the Georgia site is the
Health District 3 (HD3), which contains eight counties in the metropolitan Atlanta area: Cobb,
Clayton, Dekalb, Douglas, Gwinnett, Fulton, Newton, and Rockdale (Figure 1). Therefore, this
study includes confirmed CRE cases in HD3.
3.2 Case Definition
In order to be considered a case, the specimen must be, initially, collected from urine or
normally sterile body site (blood, bone, pleural fluid, etc.). It must meet the phenotypic case
definition, and the patient must be a resident of the surveillance area (HD3). The phenotypic case
definition from 2011-2015 (study period 1) required that the isolate be nonsusceptible to at least
one of the following carbapenems: doripenem, meropenem, or imipenem AND resistant to the
following third-generation cephalosporins; ceftriaxone, cefotaxime, and ceftazidime. In 2016
(study period 2), the phenotypic case definition was changed to resistant to imipenem,
meropenem, doripenem, or ertapenem. If a new culture meeting the case definition is collected
more than 30 days after the patient’s initial positive culture, it will be reported as a new incident
case. If a positive culture is collected within 30 days after the initial positive culture than it will
be considered persistent disease and recurrent case.
Susceptibility results were closely reviewed to verify resistance. Minimum Inhibitory
Concentrations (MIC) were established using the Clinical and Laboratory Standards Institute
(CLSI), Seventieth Information Supplement (M100-S26) (Outreach Working Group of the CLSI
Subcommittee on Antimicrobial Susceptibility Testing, 2016)
3.3 Data Collection
Cases of CRE are identified through querying of automated testing instruments at clinical
laboratories serving residents of the surveillance population (Reno et al., 2014). Epidemiological
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data included: are captured through retrospective medical record review for all incident cases by
trained EIP staff members. Epidemiological data extracted include: demographic data,
underlying conditions, location of culture collection, types of infection associated with the
positive culture, outcome, susceptibility testing results, risk factors/healthcare exposures
(including invasive devices, residence in long-term care facilities, previous
hospitalizations/surgeries, travel).
3.4 Data Analysis
The following variables were included in this analysis: age-group, year of incident and
corresponding study period, gender, race, ethnicity, CRE diagnosis, origin of incident (whether a
case was nosocomial, transferred from an LTCF, or other), and outcome (whether a patient
survived or died). Variables pertaining to healthcare exposures were also examined: residence in
a long-term care facility within year before date of initial culture, culture collection at least 3
calendar days after hospital admission, hospitalization in ICU in the 7 days prior or after to their
initial culture, hospitalization or surgery in the previous year before date of initial culture, and
admission to a LTACH wihin year before initial culture date. Other risk factors for CRE
infection or other epidemiologically significant information were chronic dialysis within year
before date of initial culture, culture source (urine or invasive, from normally sterile site),
presence of indwelling devices (i.e. urinary catheter, central vascular catheter, tracheostomy, etc)
in place on the day of culture or at any time in the 2 calendar days prior to initial culture, and
comorbidities (diabetes, immunocompromised, HIV, etc.)
Data were analyzed using SAS software (v. 9.4). Cumulative incidence rates were
calculated using Census Bureau data from 2011-2016 per 100,000 population ( Data Access and
Dissemination Systems (DADS), 2018). Univariable demographic and risk factor comparisons
were done between patients with positive urine or sterile site cultures. Chi2 or Fisher’s exact tests
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were calucated for categorical variables. P-values <0.05 were considered significant. Univariable
logistic regression was done with each risk factor as the sole predictor of outcomes of invasive
infection by study period. Multivariable modeling was conducted using invasive infection as the
outcome of interest and the new case definition as the primary exposure. Backward, forward,
stepwise, and manual selection techniques utilized to identify the best-fitting model at p<0.05.
Variables were used in the final multivariable model to control for each covariate. The model
included culture source type as the dichotomous outcome variable and predictors (old and new
case definition, hospitalization three days or more of initial culture, hospitalization in the year
prior to the initial culture, presence of a urinary catheter, central venous catheter, or other
indwelling devices.
4. RESULTS
4.1 Descriptive Analysis
A total of 1,144 confirmed cases of CRE infections were reported from 2011-2016 in
HD3. In study period 1, the population in the HD3 increased from 3,753,452 (38% of the state
population) to 3,991,607 (39% of the state population). The first study period consists of 757
CRE cases, of which 149 (19.7%) were invasive infections. The second study period had 387
CRE cases, with 31 (2.7%) that were invasive infection. In both periods, the number of noninvasive CRE infections greatly exceeded the number of invasive infections (blood and all other
sterile sites) (Figures 2-3) (Tables 3-4).
From 2011 to 2016, 8.5% (97/1144) of all CRE infections resulted in death. We
measured outcome at 30 days for non-hospitalized patients or at discharge from acute care
hospital for hospitalized patients. There were more deaths in the first period than in the second,
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as study period one had more years; 72/757 vs. 25/387 respectively (Table 3-4). During study
period 1, however the mortality rate for invasive CRE infections increased from 3.8 to 6.7, butTable 3: Study Period 1 Patient Characteristics by Culture Source
Participant Characteristics

INVASIVE
149 (19.7)

NON-INVASIVE
608 (80.3)

Overall
N=757

**Age Group
0-9
10-19
20-29
30-39
40-49
50-59
60-69
70-79
80-89
90+

3 (13.6)
0
14 (40.0)
16 (42.1)
14 (24.1)
28 (23.9)
37 (21.3)
16 (12.6)
11 (11.9)
2 (6.9)

19 (86.4)
3 (100.0)
21 (60.0)
22 (57.9)
44 (75.9)
89 (76.1)
137 (78.8)
111 (87.4)
81 (88.0)
28 (93.3)

22
3
35
38
58
117
174
127
92
30

<.0001

**Gender
Female
Male

76 (17.9)
73 (22.1)

349 (82.1)
258 (77.9)

425
331

.3176

**Race
American Indian
Asian
Black
White

0
4 (44.4)
95 (21.9)
40 (16.5)

1 (100.0)
5 (55.6)
339 (78.1)
203 (83.5)

1
9
434
243

0.0931

**Ethnicity
Hispanic or Latino
Non-Hispanic or Latino

6 (27.3)
88 (19.5)

16 (72.7)
363 (80.5)

22
451

0.6610

**Location of Culture
ER
ICU
LTACH
LTCF
OBS
OPCL
OPSUR
OR
OTHIP
OTHOP
RAD

37 (19.1)
34 (38.6)
7 (20.6)
6 (3.3)
0
2 (4.4)
0
4 (66.7)
53 (28.8)
3 (21.4)
2 (100.0)

157 ( 80.9)
54 (61.4)
27 (79.4)
175 (96.7)
3 (100.0)
43 (95.6)
1 (100.0)
2 (33.3)
131 (71.2)
11 (78.6)
0

194
88
34
181
3
45
1
6
184
14
2

<.0001

**Outcome
Died
Survived

26 (36.1)
123 (18.7)

46 (63.9)
534 (81.3)

72
657

<.0001

p-value

**Missing: Age group(61). Variables: Origin of Culture indicates whether a case was nosocomial, transferred from a longterm care facility (LTCF), or other
Chi-square was used to calculate p-values using 95 % confidence interval (CI) for the association between patient character and culture source pre-case definition (2011-2015)
Origin of Culture variable abbreviations: CU=ICU, OR=Surgery/OR, RAD=Radiology, OTHIP=Other Hospital IP Unit, ER=Emergency Room, OPCL=Outpatient Clinic/Doctor's office
OPSUR=Outpatient Surgery, OTHOP=Other Outpatient, DIAL=Dialysis Center, OTHER = Other, OBS=Observational Unit/Clinical Decision Unit, LTCF=LTCF, LTACH=LTACH,
AUTO=Autopsy, and UNK=Unknown.

peaked at 9.8 in 2014 (Figure 3). During the same period, the mortality rate for non-invasive
infections increased from 1.3 to 2.5 per 100,000 but peaked at 6.4 in 2013. In the second study
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period, the mortality rate for invasive infections increased to 4.5. and to 2.5 per 100,000 for
non-invasive infection (Figure 3).

Table 4: Study Period 2 Patient Characteristics by Culture Source
Participant Characteristics

Invasive
31 (8.1)

Non-Invasive
356 (91.9)

Overall
N=387

**Age Group
0-9
10-19
20-29
30-39
40-49
50-59
60-69
70-79
80-89
90+

0
1 (25.0)
1 (5.9)
2 (6.9)
2 (7.4)
4 (11.4)
7 (8.4)
7 (8.2)
2 (3.9)
2 (9.5)

7 (100.0)
3 (75.0)
16 (94.1)
27(93.1)
25 (92.6)
31 (88.6)
76 (91.6)
78 (91.8)
49 (96.1)
19 (90.5)

7
4
17
29
27
35
83
85
51
21

<.8959

**Gender
Female
Male

10 (4.7)
21 (12.3)

205 (95.4)
150 (87.7)

215
171

0.0222

**Race
American Indian
Asian
Black
White

0
3 (21.4)
20 (11.8)
7 (4.6)

0
11 (78.6)
150 (88.2)
145 (95.4)

0
14
170
152

0.0094

**Ethnicity
Hispanic or Latino
Non-Hispanic or Latino

1 (7.7)
30 (9.0)

12 (92.3)
305 (91.0)

13
335

0.1643

**Location of Culture
ER
ICU
LTACH
LTCF
OBS
OPCL
OPSUR
OR
OTHIP
OTHOP
OTH

3 (3.1)
9 (36.0)
4 (18.2)
0
0
1 (1.4)
0
4 (80.0)
10 (12.9)
0
0

93 (96.9)
16 (64.0)
18 (81.8)
80 (100.0)
1 (100.0)
72 (98.6)
1 (100.0)
1 (20.0)
67 (87.0)
1 (100.0)
3 (100.0)

96
25
22
80
1
73
1
5
77
1
3

<.0001

**Outcome
Died
Survived

9 (36.0)
22 (6.6)

16 (64.0)
311 (93.4)

25
333

<.0001

p-value

**Missing: Age group(28) & Outcome (1). Variables: Origin of Culture indicates whether a case was nosocomial, transferred from a longterm care facility (LTCF), or other
Chi-square was used to calculate p-values using 95 % confidence interval (CI) for the association between patient character and culture source for post case definition change (2016)
Origin of Culture variable abbreviations: CU=ICU, OR=Surgery/OR, RAD=Radiology, OTHIP=Other Hospital IP Unit, ER=Emergency Room, OPCL=Outpatient Clinic/Doctor's office
OPSUR=Outpatient Surgery, OTHOP=Other Outpatient, DIAL=Dialysis Center, OTHER = Other, OBS=Observational Unit/Clinical Decision Unit, LTCF=LTCF, LTACH=LTACH,
AUTO=Autopsy, and UNK=Unknown.

Much of the disease burden of all CRE infections, in both study periods, was between
ages 60-69; 22.9% and 21.5% respectively (Tables 3-4). All subjects in the dataset were
stratified into ten age groups.
30

Females accounted for the majority of CRE infections in both periods; 56.1% and 55.6%
respectfully (Tables 3-4). Blacks had the greatest number of CRE infections, invasive and noninvasive, before and after the case definition change; 57.3% (170/387) and 43.9% (434/757)
(Tables 3-4). In the first study period, most cultures were originally collected from the
emergency room-ER, 194 (25.6%), an LTCF 181 (23.9%), other hospital in-patient unit-OTHIP
184 (24.3%), or ICU 88 (11.6%) (Table 3). Similarly, most cultures in the second study period
were collected in the ER 96 (24.8%), LTCF 80 (100.00%), OTHIP 77 (19.9%), or outpatient
clinic/doctor's office-OPCL 73 (18.9%) (Table 4).
CRE incidence rates for both invasive and non-invasive infections decreased during study
period 1 from 9.4 to 2.5 per 100,000 (Figure 2). These rates continued to decrease in study
period 2 to 1.6 per 100, 000, following the CRE case definition change.
Figure 2: Crude Annual Cumulative Incidence of CRE Cases in HD3
10
8.9
9
7.6

CRE Rate Per 100,000

8
7

6
5
4

5.4
4.6
2.6

2.9

3.1

2.9

3
2.2

2

3.2

2.3

2.1

2.7
1.8

1.9

1
0
2010

2011

2012

2013

2014

2015

Year
Invasive

Non-Invasive

31

Total

1.3

1.1
1

2016

2017

Figure 3: Crude Annual Mortality Rate for CRE Deaths in HD3
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Figure 4: CRE Cases by Culture Source Per Study Period
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4.2 CRE Organism Distribution
The distribution of CREs prior to the case definition change shows that Klebsiella
pneumoniae infections accounted for 64% (488) of all CRE infections; 14.8% (112) of which
were invasive (Figure 4). Escherichia coli CRE infections 18.8% (114) were the second most
common in this sample, with 8.7% (13) (Figure 4). Distributions for the remaining CRE
infections were as were: Enterobacter aerogenes 5.4% (8), Enterobacter cloacae 9.4% (14), and
Klebsiella oxytoca 2% (0.3). Most these infections were non-invasive as well. In study period 1,
Escherichia coli CRE infections, 34.9% (135), were the second most present in this sample, with
16.1% (5) (Figure 5).
Figure 5: Organism Distribution
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The distribution of CREs in the second study period reveals that Klebsiella pneumoniae
infections accounted for 36.7% (142) of all CRE infections during 2016; 41.9% (13) of these
infections were invasive (Figure 5). Percentages for the remaining CRE infections were:
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Enterobacter aerogenes-15% (3.9), Enterobacter cloacae-22.5% (87), and Klebsiella oxytoca
2.1% (8) (Figure 5). In both study periods, most CRE infections were non-invasive.
4.3 Risk Factors
For study period 1, the relationship between eleven risk factors for CRE infections and
invasive infections was assessed (see Table 5). Of these risk factors, having chronic dialysis and
being hospitalized for three or more days during culture collection showed the greatest
percentages. Of those with chronic dialysis, 39.6% (36/91) were invasive. For those hospitalized
for three or more days at the time of culture collection, 34.3% (50/146) were invasive.
Percentages of invasive infections in patients with the following risk factors were similar; central
venous catheters 33.1% (83/251 cases), indwelling devices 27.5% (83/302), and surgery in the
year prior to culture collection 27.1% (51/188). All five risk factors were statistically significant
with p-values <.0001.
Table 5: Study Period 1 - Risk Factors for Invasive Infection
Risk Factors

Non-Invasive
608 (80.3)
62 (66.0)

Overall
N=757
94

pvalue

ICU prior to positive culture

Invasive
149 (19.7)
32 (34.0)

Hospitalized for ≥3 days
Hospitalized in the last year

50 (34.2)
97 (18.7)

96 (65.8)
423 (81.3)

146
520

<.0001
.0049

Surgery within the last year

51 (27.1)

137 (72.9)

188

<.0001

Urinary catheter present

69 (17.6)

323 (82.4)

392

.2492

Central venous catheter

83 (33.1)

168 (66.9)

251

<.0001

Other indwelling device

83 (27.5)

219 (72.5)

302

<.0001

In an LTCF in the year prior

46 (11.6)

350 (88.4)

396

.0004

In an LTACH in the year prior

20 (24.4)

62 (75.6)

82

.0309

Chronic dialysis

36 (39.6)

55 (60.4)

91

<.0001

Immunocompromised

84 (18.5)

370 (81.5)

454

.0289

<.0001

Chi-square was used to calculate p-values using 95 % confidence interval (CI) for the association between patient risk factors and
culture source for pre-CRE case definition change (2011-2015).
Abbreviation: ICU-Intensive Care Unit and LTACH-longterm acute care hospital.
Variable information: data for variables regarding culture collection “after hospitalized for ≥ 3 days” or “ in an LTACH in the
previous year” was largely incomplete; Immunocompromised is a composite variable comprised of diabetes, chronic renal failure,
solid tumor malignancy, connective tissue disease, solid organ transplant metastatic solid tumor, cirrhosis/liver failure, AIDS,
hematologic malignancy.

Similar percentages were reported in the second study period. The top five most notable
predictors of invasive CRE infections were stay in the ICU, hospitalization for three or more
days at the time of culture collection, the presence of a central venous catheter, chronic dialysis,
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and stay in LTACH in the year prior to original collection (see Table 6). Of which, stay in the
ICU (34) and chronic dialysis (29) presented the highest percentages for invasive infections;
41.2% (14/34) and 31.1% (9/29) respectively. Percentages of the patients with the other
riskfactors in this subset, that had invasive infections were hospitalization for three or more days
at the time of culture collection 29.5% (18/61), central venous catheters 25.3% (23/91 cases), and
stay in LTACH in the year prior to original culture collection 21.9% (9/41). All five risk factors
were statistically significant with p-values no greater than .0016.
Table 6: Study Period 2 - Risk Factors for Invasive Infection
Risk Factors

Non-Invasive
356 (91.9)
20 (58.8)

Overall
N=387
34

pvalue

ICU prior to positive culture

Invasive
31 (8.1)
14 (41.2)

Hospitalized for ≥3 days
Hospitalized in the last year

18 (24.5)
23 (10.9)

43 (75.5)
188 (89.1)

61
211

<.0001
.1076

Surgery within the last year

13 (12.6)

90 (87.4)

103

.1084

Urinary catheter present

22 (12.2)

158 (87.8)

180

.0259

Central venous catheter

23 (25.3)

68 (74.7)

91

<.0001

Other indwelling device

21 (21.0)

79 (79.0)

100

<.0001

In an LTCF in the year prior

10 (8.3)

111 (91.7)

121

.8071

In an LTACH in the year prior

9 (22.0)

32 (78.0)

41

.0016

Chronic dialysis

9 (31.1)

20 (68.9)

29

<.0001

Immunocompromised

21 (10.3)

183 (89.7)

204

.2683

<.0001

Chi-square was used to calculate p-values using 95 % confidence interval (CI) for the association between
patient risk factors and culture source for pre-CRE case definition change (2016).
Abbreviation: ICU-Intensive Care Unit and LTACH-longterm acute care hospital.
Variable information: Immunocompromised is a composite variable comprised of diabetes, chronic renal failure,
solid tumor malignancy, connective tissue disease, solid organ transplant metastatic solid tumor, cirrhosis/liver
failure, AIDS, hematologic malignancy.

In both study periods, having a central venous catheter, hospitalization for three or more
days at the time of culture collection and chronic dialysis are among the top five most prevalent
risk factors for the invasive CRE infections. However, not all risk factors being study periods are
statistically significant. For example though statistically significant in as a prevalent risk factor
for invasive CRE infections post case definition change, the presence of a urinary catheter was
not statistically signicant pre-case definition change (p=.2492). On the other hand, after the case
definition change, unlike those in study period one, some risk factors were not statistically
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significant; hospitalization in the last year (p=.1076), surgery within the last year (p=.1084),
being immunocompromised (p=.2683), and stay in an LTCF in the previous year (p=.8071).
4.4 Univariable Analysis
A univariable logistic regression analysis was conducted to gauge the strength of the
association between the eleven risk factors for CRE infections and invasive infection with both
study periods.
Table 7: Study Period 1 - Risk Factors for Invasive Infection
Risk Factors

*Crude OR

95% CI

Adjusted OR

95% CI

Central venous catheter

6.8

4.7-9.8

*5.9

3.9-8.9

Other indwelling device
Immunocompromised

4.6
1.6

3.2-6.6
1.1-2.3

*4.0
*1.6

2.7-6.1
1.1-2.4

Surgery within the last year

2.3

1.6-3.3

*2.6

1.7-3.9

Hospitalized in the last year

2.1

1.4-3.1

*1.9

1.2-3.1

Hospitalized for ≥3 days

4.7

3.-6.8

*3.9

2.6-5.9

ICU prior to positive culture

4.4

2.9-6.6

*3.1

1.9-4.5

In an LTCF in the year prior

0.6

0.5-0.9

*0.5

0.3-0.7

In an LTACH in the year prior

2.2

1.4-3.4

*1.8

1.1-3.1

Urinary catheter present

1.5

1.1-2.1

1.3

0.8-1.9

Chronic dialysis

4.9

3.3-7.5

*4.1

2.7-7.1

Chi-square was used to calculate p-values using 95 % confidence interval (CI) for the association between patient risk factors and
culture source for pre-CRE case definition change (2011-2015). *denotes statistical significance.
Abbreviation: ICU-Intensive Care Unit and LTACH-longterm acute care hospital.
Variable information: data for variables regarding culture collection “after hospitalized for ≥ 3 days” or “ in an LTACH in the
previous year” was largely incomplete; Immunocompromised is a composite variable comprised of diabetes, chronic renal failure,
solid tumor malignancy, connective tissue disease, solid organ transplant metastatic solid tumor, cirrhosis/liver failure, AIDS,
hematologic malignancy.

Table 8: Study Period 2 - Risk Factors for Invasive Infection
Risk Factors

*Crude OR

95% CI

Adjusted OR

95%CI

Central venous catheter

6.8

4.7-9.8

*8.8

4.01-18.9

Other indwelling device

4.6

3.2-6.6

*5.6

2.7-11.7

Immunocompromised

1.6

1.1-2.3

1.5

0.7-3.1

Surgery within the last year

2.3

1.6-3.3

1.8

0.9-3.8

Hospitalized in the last year

2.1

1.4-3.1

1.8

0.9-3.9

Hospitalized for ≥3 days

4.7

3.3-6.8

*8.1

3.9-17.1

ICU prior to positive culture

4.4

2.9-6.6

*11.2

4.9-25.6

In an LTCF in the year prior

0.6

0.5-0.9

0.91

0.4-1.9

In an LTACH in the year prior

2.2

1.4-3.4

*3.6

1.6-8.4

Urinary catheter present

1.5

1.1-2.1

*2.3

1.1-4.7

Chronic dialysis

4.9

3.3-7.5

*5.9

2.5-14.5

Chi-square was used to calculate p-values using 95 % confidence interval (CI) for the association between patient risk factors and
culture source for pre-CRE case definition change (2016). * denotes statistical significance.
Abbreviation: ICU-Intensive Care Unit and LTACH-longterm acute care hospital.
Variable information: Immunocompromised is a composite variable comprised diabetes, chronic renal failure, solid tumor
malignancy, connective tissue disease, solid organ transplant metastatic solid tumor, cirrhosis/liver failure, AIDS, hematologic
malignancy.
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In the study period 1, the presence of a central venous catheter was strongly associated
with invasive CRE infections (OR 5.9, 95% CI 1.4 - 4.3). Thus, cases involving a central venous
catheter in this study were 5.9 times more likely to have an invasive infection than those without
a central venous catheter. There were strong associations found between invasive CRE infection
and other risk factors as well; chronic dialysis (4.4, 95% CI 2.7-7.1) and other indwelling devices
(4.0, 95% CI 2.7-6.1).
In the study period 2, staying in an ICU prior to having a positive culture had the
strongest association with invasive CRE infections (OR 11.2, 95% CI 4.91-25.6). Patients with
ICU stay in prior seven days are 11.2 times more likely to have an invasive CRE culture than
patients that did not have an ICU stay in previous seven days.
Along with ICU status prior to having a positive culture, markedly strong associations
were found invasive CRE infections and the following risk factors: central venous catheter (OR
8.8 , 95% CI 4.1-18.9), or other indwelling devices (OR 5.6, 95% CI 2.7-11.7), and
hospitalization for three of more days (OR 8.1, 95% CI 3.9-17.1)
4.5 Multivariable Analysis
A multivariable logistic regression model was constructed to test the following
hypothesis: If the current CDC CRE surveillance definition was designed to be more simple and
sensitive, surveillance efforts in Atlanta should have an impact on patient profiles. This analysis
was performed using invasive infection as the outcome of interest and study period (pre and post
case definition change) as the predictor of interest. Manual, backward, forward, stepwise
selection methods were employed to ascertain the best-fitting model (Figure 6).

37

Figure 6: Final Multivariable Logistic Regression Model of the Association between New
Case Definition and Invasive CRE Infections
Logit Invasive AND Non Invasive CRE Infections = β 0 + β 1(New Case Definition) +
β2(Hospitalized >= 3 days) + β3(Hospitalized in the year prior) +
β4(Central venous catheter present) + β5(Other indwelling device) + β6(LTCF )+
β7(Chronic Dialysis)
Logit 𝐼𝑛𝑣𝑎𝑠𝑖𝑣𝑒 𝐶𝑅𝐸 𝐼𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛𝑠 (𝑁𝑒𝑤 𝐶𝑎𝑠𝑒 𝐷𝑒𝑓𝑖𝑛𝑖𝑡𝑖𝑜𝑛) = β 0 + β 1(1) + β2(1) + β3(1) + β4(1) + β5(1) + β6(1) + β7(1)
Logit 𝐼𝑛𝑣𝑎𝑠𝑖𝑣𝑒 𝐶𝑅𝐸 𝐼𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛𝑠 (𝑂𝑙𝑑 𝐶𝑎𝑠𝑒 𝐷𝑒𝑓𝑖𝑛𝑖𝑡𝑖𝑜𝑛 ) = β 0 + β 1(0) + β2(1) + β3(1) + β4(1) + β5(1) + β6(1) + β7(1)
*These covariates were pulled from literature and exhibit statistically significant bivariate associations.
The final model was derived from stepwise selection.

Table 9: Final Multivariable Model for the Association
between New Case Definition and Invasive CRE Infection
Covariates
Hospitalized >=3 days
No
Yes

Crude OR

Adjusted OR

1.00
*4.7 (3.3-6.8)

1.00
*8.11(3.9-17.1)

Hospitalized in the prior year
No
Yes

1.00
*2.1 (1.4-3.1)

1.00
1.84 (0.9-3.9)

Central Venous Catheter present
No
Yes

1.00
*6.8 (4.7-9.8)

1.00
*8.76 (4.1-18.9)

Other indwelling device
No
Yes

1.00
*4.6 (3.2-6.6)

1.00
*5.68 (2.7-11.7)

Chronic Dialysis
No
Yes

1.00
*4.9 (3.3-7.5)

1.00
*5.99 (2.5-14.5)

LTCF
No
Yes

1.00
*0.6 (0.5-0.9)

1.00
0.91 (0.4-1.9)

Case Definition
Old
New

1.00
*0.5 (0.3-0.8)

1.00
*0.61 (0.4-0.9)

* Indicates statistical significance.Multivariable logistic regression; adjusted model included the following
covariates:Study Period Case Definition, Hospitalized >=3 days, Hospitalized in the year prior, central venous
catheter present, other indwelling device, chronic dialysis, and stay in longterm care facility. Old case definition was
reference group. * Indicates statistical significance. All ORs were statistically significant.

In multivariable analysis new case definition (OR 0.6, 95% CI 0.4-0.9), culture ≥ 3 days
(OR 8.1, 95% CI 3.9-17.1), hospitalization in ≤1 year (OR 1.8, 95% CI 0.9-3.9), central venous
catheter (OR 8.8, 95% CI 4.08-18.9), other indwelling device (OR 5.7, 95% CI 2.7-11.7),
chronic dialysis (OR 5.9, 95% CI 2.5-14.5), and LTCF (OR 0.9, 95% 0.4-1.9) predicted invasive
CRE infection (Table 9).
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5. DISCUSSION AND CONCLUSION
Regarding culture source, the final results in the analysis show how the new case
definition change may have impacted the patient population under surveillance. For instance,
2016 had the highest number non-invasive infections of all previous years in the study. The
heaviest burden of disease remains among CRE patients 60-69 years of age in both study
periods. Further, although most cultures were originally collected in the ER, LTCF, and OTHIP
for both study periods, a more substantial number of cultures were collected in OPCLs in the
first study period and a greater number of cultures were collected in ICUs in the second study
period (Table 3-4).
The univariable analysis revealed presence of a central venous catheter to have the
strongest association with invasive CRE infections (OR 5.9, 95% CI 1.4 - 4.3). In the second
study period, staying in an ICU prior to having a positive culture had the strongest association
with invasive CRE infections (OR 11.2, 95% CI 4.9-25.6).
Though slightly, the new case definition is predictive of invasive infections. Controling
for notable risk factors, cases of CRE infections in the metropolitan Atlanta area following the
new CRE case definition change had a 40% lower odds of invasive infections than that of the
previous case definition. Ultimately, considering the limitations in this analysis, it is uncertain
whether the new case definition directly led to this shift. Perhaps this impact is indicative of a
more effective case definition as it was intended for the new case definition to be more specific
and sensitive in detecting CRE infections. Nevertheless, this association warrants further
investigation as few studies have examined the impact of the new CRE case definition on CRE
surveillance efforts. The ability to more accurately capture invasive CRE infections is paramount
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in controlling the spread of CRE, as invasive infections are far more severe than non-invasive
infections.
3.5 Limitations
There are some limitations restricting the results of this study. The new case definition was
also designed to capture more carbapenemase-producing CREs, however it is unclear if this goal
was met regarding this sample as the presence of a carbapenemase was unknown for the majority
of cases. Thus, the MuGSI surveillance personnel, are unable to evaluate sensitivity and
specificity for detecting carbapenemase. The surveillance population is not representative of
entire state or country, which produces low generalizability of results. Susceptibility testing
capabilities may differ across laboratories and some testing instruments may not test low enough
to detect non-susceptibility during 2011-2015. Lastly, not all reference labs serving the
catchment area participated therefore CRE burden may be underestimated.
5.2 Recommendations and Future Studies
Moving forward, the Georgia EIP MuGSI surveillance efforts should differentiate CPCREs from all other CREs in future samples, as this was a key goal for employing the new
definition. Including and examining these elements, would help create a clearer picture of how
the new case definition is being employed across the HD3 catchment area.
In short, the initial CDC CRE case definition, with its limited carbapenem criteria and
poor ability to detect some CP-CREs, proved to be inadequate in identifying CREs (Chea et al.,
2015). Case criteria that include non-susceptibility to any one of the four carbapenems is
certainly simpler and capable of missing carbapenemase-producing strains, but with potential for
capturing more non-carbapenemase producing CRE (Humphries & McKinnell, 2016). Thus,
readjustments to the CRE case definition in the future may be necessary. All pathogens that are
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resistant to a carbapenem represent isolates with high levels of drug resistance and warrant
utilization of prevention and control strategies such as contact precautions to mitigate
transmission. Medical facilities in Atlanta and beyond, could opt to designate more direct
interventions, such as screening patient contacts and patient cohorting, for cases with cultures
that meet these new criteria (Chea et al., 2015). Medical facilities desiring to curtail the work
and cost that comes with more aggressive prevention and control strategies could conduct
resistance-mechanism testing on cultures meeting the criteria outlined in the new case definition
and reserve interventions for the isolates that show the production of carbapenemases (Chea et
al., 2015).
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